Depressive, negative and positive symptoms in schizophrenia

Response to different dosages of haloperidol

M. C. Mauri, V. Laini, C. P C Steinhilber, L. Boscati

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

81 chronic schizophrenic in-patients during a riexacerbation phase, were included into the study. The patients were treated with HL from 1.50 to 18.00 mg p.o., t.i.d. No significant correlations were found among HRSD, SANS and SAPS. All the patients showed a significant amelioration at BPRS, HRSD, SAPS and SANS at the HL dosage below 0.2 mg/kg (<8.5 mg/die), while at the dosage up to 0.2 mg/kg (≤ 14.8 mg/die), they showed an amelioration only at BPRS and SAPS. Upper dosages of HL seem to show their efficacy on productive symptoms, while the efficacy on negative and depressive symptoms appeared only at lower dosages.

Original languageEnglish
Pages (from-to)59-63
Number of pages5
JournalNew Trends in Experimental and Clinical Psychiatry
Volume14
Issue number1
Publication statusPublished - 1998

Fingerprint

Haloperidol
Schizophrenia
Depression

Keywords

  • Depressive
  • Haloperidol dosages
  • Negative-positive symptoms
  • Schizophrenia

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Depressive, negative and positive symptoms in schizophrenia : Response to different dosages of haloperidol. / Mauri, M. C.; Laini, V.; Steinhilber, C. P C; Boscati, L.

In: New Trends in Experimental and Clinical Psychiatry, Vol. 14, No. 1, 1998, p. 59-63.

Research output: Contribution to journalArticle

@article{fbe54838268440678c7013c8c98dcb36,
title = "Depressive, negative and positive symptoms in schizophrenia: Response to different dosages of haloperidol",
abstract = "81 chronic schizophrenic in-patients during a riexacerbation phase, were included into the study. The patients were treated with HL from 1.50 to 18.00 mg p.o., t.i.d. No significant correlations were found among HRSD, SANS and SAPS. All the patients showed a significant amelioration at BPRS, HRSD, SAPS and SANS at the HL dosage below 0.2 mg/kg (<8.5 mg/die), while at the dosage up to 0.2 mg/kg (≤ 14.8 mg/die), they showed an amelioration only at BPRS and SAPS. Upper dosages of HL seem to show their efficacy on productive symptoms, while the efficacy on negative and depressive symptoms appeared only at lower dosages.",
keywords = "Depressive, Haloperidol dosages, Negative-positive symptoms, Schizophrenia",
author = "Mauri, {M. C.} and V. Laini and Steinhilber, {C. P C} and L. Boscati",
year = "1998",
language = "English",
volume = "14",
pages = "59--63",
journal = "New Trends in Experimental and Clinical Psychiatry",
issn = "0393-5310",
publisher = "CIC Edizioni Internazionali s.r.l.",
number = "1",

}

TY - JOUR

T1 - Depressive, negative and positive symptoms in schizophrenia

T2 - Response to different dosages of haloperidol

AU - Mauri, M. C.

AU - Laini, V.

AU - Steinhilber, C. P C

AU - Boscati, L.

PY - 1998

Y1 - 1998

N2 - 81 chronic schizophrenic in-patients during a riexacerbation phase, were included into the study. The patients were treated with HL from 1.50 to 18.00 mg p.o., t.i.d. No significant correlations were found among HRSD, SANS and SAPS. All the patients showed a significant amelioration at BPRS, HRSD, SAPS and SANS at the HL dosage below 0.2 mg/kg (<8.5 mg/die), while at the dosage up to 0.2 mg/kg (≤ 14.8 mg/die), they showed an amelioration only at BPRS and SAPS. Upper dosages of HL seem to show their efficacy on productive symptoms, while the efficacy on negative and depressive symptoms appeared only at lower dosages.

AB - 81 chronic schizophrenic in-patients during a riexacerbation phase, were included into the study. The patients were treated with HL from 1.50 to 18.00 mg p.o., t.i.d. No significant correlations were found among HRSD, SANS and SAPS. All the patients showed a significant amelioration at BPRS, HRSD, SAPS and SANS at the HL dosage below 0.2 mg/kg (<8.5 mg/die), while at the dosage up to 0.2 mg/kg (≤ 14.8 mg/die), they showed an amelioration only at BPRS and SAPS. Upper dosages of HL seem to show their efficacy on productive symptoms, while the efficacy on negative and depressive symptoms appeared only at lower dosages.

KW - Depressive

KW - Haloperidol dosages

KW - Negative-positive symptoms

KW - Schizophrenia

UR - http://www.scopus.com/inward/record.url?scp=0031842724&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031842724&partnerID=8YFLogxK

M3 - Article

VL - 14

SP - 59

EP - 63

JO - New Trends in Experimental and Clinical Psychiatry

JF - New Trends in Experimental and Clinical Psychiatry

SN - 0393-5310

IS - 1

ER -